Albumin-bound paclitaxel combined with lobaplatin using different administration methods in the treatment of cervical cancer: Study on the efficacy and its effect on immune function and inflammatory response

Paclitaxel-Lobaplatin Treatment of Cervical Cancer

Abstract

Objective: To investigate the efficacy of the combination therapy of albumin-bound paclitaxel and lobaplatin in the treatment of cervical cancer, and to explore its effects on immune function and inflammatory response.

Methodology: This was a retrospective study. This study enrolled 108 cervical cancer patients admitted to The No.2 Hospital of Baoding from January 2020 to March 2024, and divided them into two groups according to different administration methods. Compared the short-term and long-term efficacy, side effects, immune functions, inflammatory factor levels, etc. between groups.

Results: Comparison of the short-term efficacy between groups showed that the intervention group had a significantly higher response rate (83.33% vs. 42.59%) and disease control rate (92.59% vs. 68.52%) than those in the drip group (P<0.05). The 2nd year survival rate (74.07% vs. 46.30%), 3rd year survival rate (64.81% vs. 29.63%) were significantly higher, and the survival time was obviously longer in the intervention group than those in the drip group (P<0.05). Furthermore, the levels of immune function indicators (Th1 and Th2) and inflammatory factors (TGF-β, IFN-γ and TNF-α) were significantly lower, while IL-10 level was obviously higher in the intervention group after treatment than those before treatment and in the drip group (P<0.05).

Conclusion: Albumin-bound paclitaxel combined with lobaplatin has a significant therapeutic effect for interventional chemoembolization of patients with cervical cancer. It may significantly improve the short-term and long-term clinical efficacy and immune function, and alleviate the inflammatory condition of cervical cancer patients.